| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: BVEX |
| Security Type |
Common Stock |
| Lead Underwriter |
Janney Montgomery Scott LLC |
| Days In Registration |
122 |
| Date Filed |
20-Jun-2006 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
BioVex Group Inc is a biotechnology company that focuses on the development and future commercialization of cancer treatments and disease preventing medicine. They are the developer of OncoVex, a technological breakthrough in virus treatment. OncoVex causes the death of cancer cells found in tumors and leaves surrounding healthy cells unharmed reducing chances of side-effects.BioVex is primarily based in Cambridge, Massachusetts and also has research facilities near Oxford, UK. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
12.32M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
3.4M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
